[go: up one dir, main page]

CL2018002149A1 - Proceso. - Google Patents

Proceso.

Info

Publication number
CL2018002149A1
CL2018002149A1 CL2018002149A CL2018002149A CL2018002149A1 CL 2018002149 A1 CL2018002149 A1 CL 2018002149A1 CL 2018002149 A CL2018002149 A CL 2018002149A CL 2018002149 A CL2018002149 A CL 2018002149A CL 2018002149 A1 CL2018002149 A1 CL 2018002149A1
Authority
CL
Chile
Prior art keywords
analogs
variants
production
same
neosaxytoxine
Prior art date
Application number
CL2018002149A
Other languages
English (en)
Inventor
Ralf Kellmann
Brett Neilan
Original Assignee
Bergen Teknologioverfoering As
Newsouth Innovations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bergen Teknologioverfoering As, Newsouth Innovations Pty Ltd filed Critical Bergen Teknologioverfoering As
Publication of CL2018002149A1 publication Critical patent/CL2018002149A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1288—Transferases for other substituted phosphate groups (2.7.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/08—Transferases for other substituted phosphate groups (2.7.8)
    • C12Y207/08007—Holo-[acyl-carrier-protein] synthase (2.7.8.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A PROCESOS PARA FABRICAR NEOSAXITOXINA, Y ANÁLOGOS Y VARIANTES DE LOS MISMOS, E INTERMEDIOS EN LA PRODUCCIÓN DE NEOSAXITOXINA EN CÉLULAS HOSPEDADORAS RECOMBINANTES. LA NEOSAXITOXINA Y LOS ANÁLOGOS Y VARIANTES DE LOS MISMOS PUEDEN USARSE EN LA PRODUCCIÓN DE COMPOSICIONES FARMACÉUTICAS.
CL2018002149A 2016-02-12 2018-08-08 Proceso. CL2018002149A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1602576.9A GB201602576D0 (en) 2016-02-12 2016-02-12 Process

Publications (1)

Publication Number Publication Date
CL2018002149A1 true CL2018002149A1 (es) 2019-02-15

Family

ID=55697646

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002149A CL2018002149A1 (es) 2016-02-12 2018-08-08 Proceso.

Country Status (14)

Country Link
US (2) US10920256B2 (es)
EP (2) EP4279577A3 (es)
JP (1) JP2019504650A (es)
KR (1) KR20190006478A (es)
CN (1) CN109790558A (es)
AU (2) AU2017218598B2 (es)
BR (1) BR112018016346A2 (es)
CA (1) CA3014109A1 (es)
CL (1) CL2018002149A1 (es)
EA (1) EA201891805A1 (es)
GB (3) GB201602576D0 (es)
IL (1) IL261106A (es)
MX (1) MX2018009676A (es)
WO (1) WO2017137606A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109097415A (zh) * 2018-08-08 2018-12-28 浙江海洋大学 一种利用产毒海洋亚硫酸杆菌发酵制备石房蛤毒素的方法
WO2021191848A1 (en) * 2020-03-26 2021-09-30 The Cawthron Institute Trust Board Preparation of neosaxitoxin
CN115466219B (zh) * 2022-07-28 2023-09-08 中国科学院天津工业生物技术研究所 一种1-[3-(2-氨基-4-乙基-1h-咪唑-5-基)丙基]胍的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2159510A1 (en) 1993-04-08 1994-10-27 David A. Horne Method for the synthesis of 4- and/or 5-(di)substituted 2-aminoimidazoles from 2-aminoimidazoles and aldehydes
AU7389098A (en) 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
JP4289694B2 (ja) 1998-04-03 2009-07-01 正昭 児玉 新規のサキシトキシン誘導体およびその製造方法
WO2002048671A1 (en) 2000-12-12 2002-06-20 Australian Institute Of Marine Science Assay for paralytic shellfish toxin
JP2003012699A (ja) 2001-07-04 2003-01-15 Japan Science & Technology Corp 抗麻酔性貝毒抗体の製法、新規抗体、該抗体を用いるｅｌｉｓａ測定キット、該製法による系標識毒標品
EA006739B1 (ru) 2001-11-15 2006-04-28 Майкроу Элджи Корпорейшн Фармацевтические композиции, содержащие 3,4-пропинопергидропурины, и их применение для блокирования нейронной передачи
US20030148359A1 (en) 2002-01-11 2003-08-07 Yale University Saxitoxin detection and assay method
AU2003901897A0 (en) 2003-02-12 2003-05-08 Australian Institute Of Marine Science Conjugate
EP1799219A1 (en) 2004-09-21 2007-06-27 Laboratorios del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain
US20100075992A1 (en) 2004-09-22 2010-03-25 Laboratorios Del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treament of peripheral-nervously derived neuropathi pain
RU2277097C1 (ru) 2004-12-27 2006-05-27 Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) Высокомеченный тритием дигидрохлорид [3h]сакситоксина
WO2006084765A1 (en) * 2005-02-11 2006-08-17 Wex Pharmaceuticals, Inc. Use of sodium channel blockers and their analogues for the treatment of nicotine dependency
EP1928452A4 (en) 2005-08-25 2010-09-01 Wex Medical Ltd USE OF SODIUM CHANNEL BLOCKS FOR THE TREATMENT OF VISCERAL PAIN OR PAIN THROUGH CANCER TREATMENT
WO2007025213A2 (en) 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the management of musculoskeletal pain
EP1844781A1 (en) 2006-02-22 2007-10-17 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of preterm labor
EP2012774A1 (en) 2006-03-27 2009-01-14 Wex Pharmaceuticals, Inc Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
EP1844782A1 (en) 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc Use of 4,9-anhydro-tetrodotoxin for the treatment of diseases related to the voltage-gated sodium channel subunit Nav1.6
EP2142638B1 (en) * 2007-04-02 2016-11-16 NewSouth Innovations Pty Limited Methods for producing secondary metabolites
BRPI0817545A2 (pt) * 2007-10-12 2014-11-25 Univ California Microorganismo recombinante, métodos para produzir um microorganismo recombinante e para produzir isopropanol, vetor recombinante, e, célula hospedeira recombinante.
JP5722765B2 (ja) 2008-04-24 2015-05-27 ニューサウス イノベイションズ ピーティーワイ リミテッド 藍藻類サキシトキシン遺伝子クラスタおよびシアノトキシンを有する生物の検出
CL2009000723A1 (es) 2009-03-24 2009-06-19 Proteus Sa Metodo de purificacion industrial de ficotoxinas biologicamente activas que comprende proporcionar una cantidad adecuada de una fuente de ficotoxinas como por ejemplo el cultivo de un clon de cianobacterias.
US8952152B2 (en) 2009-03-24 2015-02-10 Proteus S.A. Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof
JP6186125B2 (ja) 2009-05-07 2017-08-30 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 疼痛の研究、画像化および治療方法、ならびに疼痛の研究、画像化および治療のための組成物
WO2011094367A1 (en) 2010-01-26 2011-08-04 Evans Michael A Methods, devices, and agents for denervation
US9107925B2 (en) 2010-02-10 2015-08-18 Phytotox Limited Sodium channel blocker for treatment of loss of superficial sensitivity
WO2012155202A1 (en) 2011-05-16 2012-11-22 Newsouth Innovations Pty Limited Detection of saxitoxin-producing dinoflagellates
EP2638908A1 (en) 2012-03-16 2013-09-18 Phytotox SpA Paralytic Shellfish Poison
US9408846B2 (en) 2012-04-23 2016-08-09 The Children's Medical Center Corporation Formulations and methods for delaying onset of chronic neuropathic pain
US10233219B2 (en) 2013-04-12 2019-03-19 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
EP3129381B1 (en) 2014-04-09 2020-11-04 Siteone Therapeutics Inc. 10',11'-modified saxitoxins useful for the treatment of pain

Also Published As

Publication number Publication date
EP3414334A1 (en) 2018-12-19
AU2021201969B2 (en) 2023-02-02
GB2569907B (en) 2020-04-08
EP3414334B1 (en) 2023-10-11
GB201602576D0 (en) 2016-03-30
US20190048375A1 (en) 2019-02-14
GB2552859B (en) 2019-09-18
GB201903649D0 (en) 2019-05-01
JP2019504650A (ja) 2019-02-21
AU2021201969A1 (en) 2021-04-29
CN109790558A (zh) 2019-05-21
EP4279577A2 (en) 2023-11-22
BR112018016346A2 (pt) 2019-01-22
US11566271B2 (en) 2023-01-31
AU2017218598A1 (en) 2018-10-04
GB2552859A (en) 2018-02-14
IL261106A (en) 2018-10-31
CA3014109A1 (en) 2017-08-17
US20210108239A1 (en) 2021-04-15
AU2017218598B2 (en) 2021-05-06
WO2017137606A1 (en) 2017-08-17
GB2569907A (en) 2019-07-03
EP3414334C0 (en) 2023-10-11
EP4279577A3 (en) 2024-01-24
US10920256B2 (en) 2021-02-16
KR20190006478A (ko) 2019-01-18
MX2018009676A (es) 2019-06-06
EA201891805A1 (ru) 2019-02-28
GB201702275D0 (en) 2017-03-29

Similar Documents

Publication Publication Date Title
CL2018002794A1 (es) Compuestos bicíclicos
CO2017001884A2 (es) Polimorfos de selinexor
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
UY36287A (es) COMPUESTO DE OBJETIVO A IL-23A y TNF-ALFA Y USO DEL MISMO
BR112017025398A2 (pt) formas de dosagem sólidas de palbociclib
BR112016025427A2 (pt) processos de preparação de um inibidor de jak1 e formas do mesmo
UY40486A (es) Anticuerpo anti-MASP-3, proceso para la producción del anticuerpo y composiciones
CR20160450A (es) Anticuerpos multiespecificos
BR112017025873A2 (pt) método para revestir a cabeça de um pirulito com um material de revestimento
MX2018010301A (es) Sales de derivados de piperazina obtenidas por adicion de acidos.
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
DK3312270T3 (da) Fremgangsmåde til fremstilling af plader med høj ydeevne
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
BR112017005109A2 (pt) produto refratário com base em al2o3, composição de matérias-primas para a fabricação do produto, método para a fabricação de um produto refratário, produto refratário, e emprego do produto refratário
BR112017009289A2 (pt) métodos de administrar composições de amantadina
CR20160133A (es) Derivados de fenilalanina sustituidos
MX2015015148A (es) Proceso para la preparacion de 4-hidroxi-4-metiltetrahidropiranos 2-sustituidos en una cascada de reactores.
UY36250A (es) Forma cristalina de sofosbuvir y proceso para su preparación
ES2874374T8 (es) Proceso para producir hidrógeno
HUE062005T2 (hu) Eljárások izomból származó sejtek elõállítására
CL2018002149A1 (es) Proceso.
BR112017018993A2 (pt) Processo para preparar 3-cloro-2- vinilfenilassulfonatos
MX2016013586A (es) Tinturas reactivas fluorescentes, proceso para su produccion y su uso.
BR112016023767A2 (pt) forma sólida, composição farmacêutica, compostos, métodos, composições e utilizações
ES2670477R1 (es) Procedimiento para la preparacion de la 17beta-hidroxi-des-a-androst-9,10-en-5-ona